Literature DB >> 23450234

Gastric cancer and trastuzumab: first biologic therapy in gastric cancer.

Krishna S Gunturu1, Yanghee Woo, Nike Beaubier, Helen E Remotti, M Wasif Saif.   

Abstract

Gastric cancer remains difficult to cure and has a poor overall prognosis. Chemotherapy and multimodality therapy has shown some benefit in the treatment of gastric cancer. Current therapies for gastric cancer have their limitations; thus, we are in need of newer treatment options including targeted therapies. Here, we review the biologic therapy with trastuzumab in human epidermal growth factor receptor 2 (HER2)+ gastric cancer.

Entities:  

Keywords:  gastric cancer; trastuzumab

Year:  2013        PMID： 23450234      PMCID： PMC3556876          DOI： 10.1177/1758834012469429

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  33 in total

Review 1.  CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy.

Authors:  Joon Seok Lim; Mi Jin Yun; Myeong-Jin Kim; Woo Jin Hyung; Mi-Suk Park; Jin-Young Choi; Tae-Sung Kim; Jong Doo Lee; Sung Hoon Noh; Ki Whang Kim
Journal:  Radiographics       Date:  2006 Jan-Feb       Impact factor: 5.333

2.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

3.  Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer.

Authors:  Enzo Mammano; Claudio Belluco; Manuela Sciro; Roberto Mencarelli; Marco Agostini; Mauro Michelotto; Alberto Marchet; Donato Nitti
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

4.  Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

Authors:  C Pinto; F Di Fabio; S Siena; S Cascinu; F L Rojas Llimpe; C Ceccarelli; V Mutri; L Giannetta; S Giaquinta; C Funaioli; R Berardi; C Longobardi; E Piana; A A Martoni
Journal:  Ann Oncol       Date:  2006-12-12       Impact factor: 32.976

Review 5.  FDG-PET has no definite role in preoperative imaging in gastric cancer.

Authors:  A E Dassen; D J Lips; C J Hoekstra; J F M Pruijt; K Bosscha
Journal:  Eur J Surg Oncol       Date:  2009-01-14       Impact factor: 4.424

Review 6.  HER-2 signaling and inhibition in breast cancer.

Authors:  B C Browne; N O'Brien; M J Duffy; J Crown; N O'Donovan
Journal:  Curr Cancer Drug Targets       Date:  2009-05       Impact factor: 3.428

7.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study.

Authors:  M Hofmann; O Stoss; D Shi; R Büttner; M van de Vijver; W Kim; A Ochiai; J Rüschoff; T Henkel
Journal:  Histopathology       Date:  2008-04-18       Impact factor: 5.087

8.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

9.  Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery.

Authors:  Gennaro Galizia; Eva Lieto; Michele Orditura; Paolo Castellano; Anna La Mura; Vincenzo Imperatore; Margherita Pinto; Anna Zamboli; Ferdinando De Vita; Francesca Ferraraccio
Journal:  World J Surg       Date:  2007-07       Impact factor: 3.352

10.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245
View more
  29 in total

Review 1.  Next generation sequencing-based emerging trends in molecular biology of gastric cancer.

Authors:  Renu Verma; Prakash C Sharma
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

2.  Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.

Authors:  Rabah Gahoual; Michaël Biacchi; Johana Chicher; Lauriane Kuhn; Philippe Hammann; Alain Beck; Emmanuelle Leize-Wagner; Yannis N François
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 3.  HER2 therapies and gastric cancer: a step forward.

Authors:  Ramon Andrade de Mello; Andrea Marin Marques; António Araújo
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

4.  A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.

Authors:  Cornelius F Waller; Apinya Vutikullird; Tracey E Lawrence; Andrew Shaw; Mark Shiyao Liu; Mark Baczkowski; Rajiv Sharma; Abhijit Barve; Parag Goyal; Charles Donnelly; Nilanjan Sengupta; Eduardo J Pennella
Journal:  Br J Clin Pharmacol       Date:  2018-07-31       Impact factor: 4.335

5.  Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy.

Authors:  Cai-Xia Dong; Jian-Fei Fu; Xian-Yun Ye; Xiao-Fen Li; Xian Zhong; Ying Yuan
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

6.  Genetic amplification of PPME1 in gastric and lung cancer and its potential as a novel therapeutic target.

Authors:  Jing Li; Sufang Han; Ziliang Qian; Xinying Su; Shuqiong Fan; Jiangang Fu; Yuanjie Liu; Xiaolu Yin; Zeren Gao; Jingchuan Zhang; De-Hua Yu; Qunsheng Ji
Journal:  Cancer Biol Ther       Date:  2013-11-19       Impact factor: 4.742

Review 7.  Molecular alterations in gastric cancer with special reference to the early-onset subtype.

Authors:  Małgorzata Skierucha; Anya Na Milne; G Johan A Offerhaus; Wojciech P Polkowski; Ryszard Maciejewski; Robert Sitarz
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

Review 8.  Outlooks on Epstein-Barr virus associated gastric cancer.

Authors:  Madiha Naseem; Afsaneh Barzi; Christine Brezden-Masley; Alberto Puccini; Martin D Berger; Ryuma Tokunaga; Francesca Battaglin; Shivani Soni; Michelle McSkane; Wu Zhang; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2018-03-31       Impact factor: 12.111

9.  PIWIL1 promotes gastric cancer via a piRNA-independent mechanism.

Authors:  Shuo Shi; Zhen-Zhen Yang; Sanhong Liu; Fan Yang; Haifan Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-26       Impact factor: 11.205

10.  Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1-Mediated Secretion of Extracellular Vesicles.

Authors:  Nil Grunberg; Meirav Pevsner-Fischer; Tal Goshen-Lago; Judith Diment; Yaniv Stein; Hagar Lavon; Shimrit Mayer; Oshrat Levi-Galibov; Gil Friedman; Yifat Ofir-Birin; Li-Jyun Syu; Cristina Migliore; Eyal Shimoni; Salomon M Stemmer; Baruch Brenner; Andrzej A Dlugosz; David Lyden; Neta Regev-Rudzki; Irit Ben-Aharon; Ruth Scherz-Shouval
Journal:  Cancer Res       Date:  2021-02-05       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.